1. Home
  2. SABS vs IRIX Comparison

SABS vs IRIX Comparison

Compare SABS & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SABS
  • IRIX
  • Stock Information
  • Founded
  • SABS 2014
  • IRIX 1989
  • Country
  • SABS United States
  • IRIX United States
  • Employees
  • SABS N/A
  • IRIX N/A
  • Industry
  • SABS Biotechnology: Pharmaceutical Preparations
  • IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • SABS Health Care
  • IRIX Health Care
  • Exchange
  • SABS Nasdaq
  • IRIX Nasdaq
  • Market Cap
  • SABS 23.9M
  • IRIX 28.6M
  • IPO Year
  • SABS N/A
  • IRIX 1996
  • Fundamental
  • Price
  • SABS $3.34
  • IRIX $1.69
  • Analyst Decision
  • SABS Strong Buy
  • IRIX Hold
  • Analyst Count
  • SABS 5
  • IRIX 1
  • Target Price
  • SABS $12.40
  • IRIX $2.00
  • AVG Volume (30 Days)
  • SABS 83.3K
  • IRIX 20.6K
  • Earning Date
  • SABS 11-06-2024
  • IRIX 11-12-2024
  • Dividend Yield
  • SABS N/A
  • IRIX N/A
  • EPS Growth
  • SABS N/A
  • IRIX N/A
  • EPS
  • SABS N/A
  • IRIX N/A
  • Revenue
  • SABS $1,512,723.00
  • IRIX $48,431,000.00
  • Revenue This Year
  • SABS N/A
  • IRIX N/A
  • Revenue Next Year
  • SABS N/A
  • IRIX $5.44
  • P/E Ratio
  • SABS N/A
  • IRIX N/A
  • Revenue Growth
  • SABS N/A
  • IRIX N/A
  • 52 Week Low
  • SABS $2.16
  • IRIX $1.27
  • 52 Week High
  • SABS $7.70
  • IRIX $3.65
  • Technical
  • Relative Strength Index (RSI)
  • SABS 48.06
  • IRIX 50.88
  • Support Level
  • SABS $2.75
  • IRIX $1.61
  • Resistance Level
  • SABS $4.30
  • IRIX $1.82
  • Average True Range (ATR)
  • SABS 0.51
  • IRIX 0.08
  • MACD
  • SABS 0.03
  • IRIX -0.02
  • Stochastic Oscillator
  • SABS 26.11
  • IRIX 35.94

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

About IRIX IRIDEX Corporation

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Share on Social Networks: